Enzo Biochem Debt to Equity Ratio 2010-2023 | ENZ
Current and historical debt to equity ratio values for Enzo Biochem (ENZ) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Enzo Biochem debt/equity for the three months ending January 31, 2023 was 0.01.
| Enzo Biochem Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2023-01-31 |
$0.04B |
$0.03B |
1.33 |
| 2022-10-31 |
$0.04B |
$0.05B |
0.89 |
| 2022-07-31 |
$0.04B |
$0.05B |
0.76 |
| 2022-04-30 |
$0.04B |
$0.06B |
0.67 |
| 2022-01-31 |
$0.04B |
$0.07B |
0.67 |
| 2021-10-31 |
$0.04B |
$0.07B |
0.62 |
| 2021-07-31 |
$0.05B |
$0.07B |
0.66 |
| 2021-04-30 |
$0.05B |
$0.07B |
0.75 |
| 2021-01-31 |
$0.05B |
$0.06B |
0.81 |
| 2020-10-31 |
$0.05B |
$0.06B |
0.92 |
| 2020-07-31 |
$0.05B |
$0.06B |
0.93 |
| 2020-04-30 |
$0.05B |
$0.06B |
0.87 |
| 2020-01-31 |
$0.05B |
$0.07B |
0.65 |
| 2019-10-31 |
$0.05B |
$0.08B |
0.60 |
| 2019-07-31 |
$0.02B |
$0.09B |
0.24 |
| 2019-04-30 |
$0.02B |
$0.09B |
0.22 |
| 2019-01-31 |
$0.02B |
$0.07B |
0.32 |
| 2018-10-31 |
$0.02B |
$0.08B |
0.25 |
| 2018-07-31 |
$0.02B |
$0.08B |
0.25 |
| 2018-04-30 |
$0.02B |
$0.09B |
0.22 |
| 2018-01-31 |
$0.02B |
$0.09B |
0.23 |
| 2017-10-31 |
$0.02B |
$0.09B |
0.23 |
| 2017-07-31 |
$0.02B |
$0.09B |
0.21 |
| 2017-04-30 |
$0.02B |
$0.09B |
0.20 |
| 2017-01-31 |
$0.02B |
$0.09B |
0.21 |
| 2016-10-31 |
$0.02B |
$0.09B |
0.25 |
| 2016-07-31 |
$0.02B |
$0.09B |
0.25 |
| 2016-04-30 |
$0.02B |
$0.05B |
0.44 |
| 2016-01-31 |
$0.03B |
$0.05B |
0.49 |
| 2015-10-31 |
$0.03B |
$0.05B |
0.58 |
| 2015-07-31 |
$0.03B |
$0.04B |
0.61 |
| 2015-04-30 |
$0.02B |
$0.03B |
0.72 |
| 2015-01-31 |
$0.03B |
$0.04B |
0.71 |
| 2014-10-31 |
$0.03B |
$0.04B |
0.73 |
| 2014-07-31 |
$0.03B |
$0.04B |
0.74 |
| 2014-04-30 |
$0.03B |
$0.04B |
0.65 |
| 2014-01-31 |
$0.02B |
$0.03B |
0.73 |
| 2013-10-31 |
$0.03B |
$0.03B |
0.76 |
| 2013-07-31 |
$0.03B |
$0.03B |
0.73 |
| 2013-04-30 |
$0.02B |
$0.04B |
0.63 |
| 2013-01-31 |
$0.02B |
$0.04B |
0.54 |
| 2012-10-31 |
$0.02B |
$0.05B |
0.47 |
| 2012-07-31 |
$0.02B |
$0.05B |
0.41 |
| 2012-04-30 |
$0.02B |
$0.08B |
0.25 |
| 2012-01-31 |
$0.02B |
$0.08B |
0.25 |
| 2011-10-31 |
$0.02B |
$0.08B |
0.25 |
| 2011-07-31 |
$0.02B |
$0.09B |
0.23 |
| 2011-04-30 |
$0.02B |
$0.09B |
0.20 |
| 2011-01-31 |
$0.02B |
$0.09B |
0.21 |
| 2010-10-31 |
$0.02B |
$0.10B |
0.19 |
| 2010-07-31 |
$0.02B |
$0.10B |
0.19 |
| 2010-04-30 |
$0.01B |
$0.10B |
0.14 |
| 2010-01-31 |
$0.02B |
$0.11B |
0.21 |
| 2009-10-31 |
$0.02B |
$0.12B |
0.13 |
| 2009-07-31 |
$0.02B |
$0.12B |
0.14 |
| 2009-04-30 |
$0.02B |
$0.12B |
0.15 |
| 2009-01-31 |
$0.02B |
$0.12B |
0.13 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.106B |
$0.107B |
|
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
|
